Mundipharma Announces Launch of INVOKANA and VOKANAMET in Norway for the Treatment of Type 2…
The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin,…
Read More...
Read More...
